CDRH Staff Credits Advocacy Groups For Patient Preference Guidance
This article was originally published in The Gray Sheet
Executive Summary
Top CDRH officials say while they have been working to incorporate patient preference into their regulatory process, it was the push from patients to get more involved in the agency's decision making process that led the agency to develop a new draft guidance on the topic.
You may also be interested in...
Final Guidance Encourages Use Of Patient Preference In Device Applications
US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.
Guidance: What The Patient Prefers, And How To Make It Part Of Your FDA Submission
FDA draft guidance lays out how to collect patient preference data and how to present the preferences on device labels. The guidance supports a growing emphasis by FDA to formally incorporate patient input into regulatory decision-making.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.